We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
Backed by the cutting-edge technology of Augmented Reality (AR) app, Trend Editions presents a revolutionised way of purchasing quality furniture, antiques and fabrics over the internet. It functions as a unique alternative to the traditional furniture industry. With an aim to be an AR-only UK retailer, Trend Editions has already a substantial infrastructure in place and over £150K of investment to slice their target market. Trend Editions’s high-value items are available on make-to-order basis without warehousing or showrooms.
days to go: Expired investment: £50,510
Cadello is a newly produced category-defining unique spirit produced by Distilleria Pisoni, a 150-year-old distillery in Italy. It is growing its distributors over the UK as well as Italy. The company has also partnered with Honest Grapes and other independent marketers and sales teams. Cadello has hired Italian and UK Brand Ambassadors and engaged Pegasus Spirits as UK importer and brand manager. The company will support its continued fast-paced growth by investing into its marketing and sales through tradeshows & tasting events, Brand Ambassadors, PR (editorial and events), social media & advertising, and bartending competitions.
days to go: Expired investment: £275,490
Super U is a health food brand, creating great-tasting and nutritious superfood blends and providing a natural, innovative & convenient way of consuming superfoods, without costing the Earth. The company has 3500+ online consumers and, the social audience has risen to over 8,500 followers. Additionally, Super U has been a finalist for Start-Up Business of the Year and Health & Beauty Business of the Year 2019 - for the Great British Entrepreneur Awards. The funds will be used for growth, marketing and export strategies.
days to go: Expired investment: £160,110
Eat Sleep Love is a baby boutique, providing an appointment-based service for new parents to get all the information and products needed to prepare for the arrival of their baby. The expert team will help expecting parents create and purchase from a list of chosen baby items and have them all delivered on a day convenient to you. 
days to go: Expired investment: £81,390
The Mighty Society produces a tasty, smooth and rich non-dairy substitute to milk which is made from yellow split-peas. The company is in partnership with the UK's biggest dairy substitute manufacturers, and it has sold over 66,000 units. The pea milk has been launched in 2,000 different stocking points across the UK including Sainsbury's, Marks & Spencers, Whole Foods Market and other retailers. The Mighty Society will use the funds for production, R&D, sales and marketing.
days to go: Expired investment: £443,389
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.   
days to go: Expired investment: £30,564
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph